CK2 inhibition restores IKAROS’ ability to regulate BCL2L1 (BCL-XL) expression in primary high-risk B-ALL with deletion of 1 IKZF1 allele. (A) BCL2L1 mRNA level was measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in primary high-risk B-ALL samples with deletion of 1 IKZF1 allele following treatment with 10 μM CK2 inhibitor (CX-4945) for 2 days as compared with untreated (CTRL) cells. The qChIP analysis of the occupancy of (B) IKAROS, (C) HDAC1, (D) H3K27me3, (E) H3K9ac, and (F) H3K4me3 at the BCL2L1 promoter. Untreated cells are (white and light gray bars) are compared with and CX-4945-treated primary high-risk B-ALL (dark gray and black bars). Primary high-risk ALL cells were cultured on stromal cells with or without CK2 inhibitor CX-4945 (10 μM) for 2 days. (B) ChIP enrichments are normalized to input, graphed is mean ± SD of 4 independent experiments. (C-F) ChIP enrichments are normalized to CTL-IgG samples. Graphed in panel A, panels C-F are the mean ± SD of triplicates representative of 1 of 3 independent experiments (A) or 4 independent experiments (C-F). *P < .05, **P < .01, ***P < .001, ****P < .0001.